Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LAURION Intercepts of 37.70 g/t Gold over 0.50 m, 6.60 g/t Gold over 1.00 m (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
BioVaxys Technology Corp.
C.BIOV
Alternate Symbol(s):
BVAXF
Healthcare
Biotechnology
BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical...
-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:BIOV)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 11, 2024 8:11pm
New Press Release - BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //VANCOUVER, BC, Sept. 11, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the third tranche (the "Third...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 04, 2024 7:00am
New Press Release - BioVaxys to Present New Data on its DPX Immune Educating Platform at Personalized Cancer Vaccine Summit
VANCOUVER, BC, Sept. 4, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") is pleased to announce that it has been invited to present "A Novel Delivery System for Personalized Peptide & mRNA Vaccines for More Targeted Therapies" at...
read article.
(0)
•••
JoseCuervo
X
View Profile
View Bullboard History
Post by
JoseCuervo
on Aug 29, 2024 5:03pm
Spayvac
From their Twitter: Our licensee #SpayVac-for-Wildlife Inc. reached a major milestone with the first successful scaled-up production run for their animal fertility-control vaccine at the new
...more
(298)
•••
moneywagon
X
View Profile
View Bullboard History
Post by
moneywagon
on Aug 22, 2024 11:03am
BIOV SHE'S ALIVE~HER HEART BEATS STRONG~GR8 NR~CONFERENCE
Thanks YappingDoxie @YappingDoxie Looks like BioVaxys has been selected as a speaker at a top vaccines conference later this fall! https://web.hansonwadegroup.com/rs/355-DOS-429/images
...more
(82)
•••
RockLobster1
X
View Profile
View Bullboard History
Comment by
RockLobster1
on Aug 22, 2024 9:44am
RE:New Press Release - BioVaxys DPX-Based Vaccines Exhibit Robust Efficacy Across Multiple Infectious Diseases
All looks promising... anyone else here from IMV board? Sad how badly that was managed, but the technology still has promise... hope this mgmt is better.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 22, 2024 8:34am
New Press Release - BioVaxys DPX-Based Vaccines Exhibit Robust Efficacy Across Multiple Infectious Diseases
VANCOUVER, BC, Aug. 22, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights the potential of its novel lipid-in-oil delivery platform, DPX™, across multiple infectious disease studies and announces its plans for partnering...
read article.
(0)
•••
JoseCuervo
X
View Profile
View Bullboard History
Post by
JoseCuervo
on Aug 20, 2024 3:27pm
New Passin Interview
Click to view
(5)
•••
thetradeblaizer
X
View Profile
View Bullboard History
Post by
thetradeblaizer
on Aug 19, 2024 3:29pm
BIOV Article
Great article about BIOV, Spayvac and Zoetis. Summary: SpayVac completed a new research and production facility in Wisconsin, to develop and produce long-lasting, single-dose
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 19, 2024 8:01am
New Press Release - SPAYVAC FOR WILDLIFE, INC. ANNOUNCES COMPLETION OF SPAYVAC RESEARCH AND PRODUCTION FACILITY IN MADISON, WISCONSIN
MADISON, Wis., Aug. 19, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. ("SpayVac") jointly announce that SpayVac® recently completed set-up of its new research and production facility in Madison, Wisconsin to...
read article.
(5)
•••
thetradeblaizer
X
View Profile
View Bullboard History
Post by
thetradeblaizer
on Aug 15, 2024 6:25pm
Patience
The longs here know what this company is worth. The IMV acquisition is going to print money soon. Zoetis' Q2 results were phenomenal.
(5)
•••
thetradeblaizer
X
View Profile
View Bullboard History
Post by
thetradeblaizer
on Jul 29, 2024 2:23pm
DPX
This collaboration is a game-changer! The interdisciplinary approach could revolutionize food allergy treatment. Can't wait to see how the DPX platform's flexibility translates to real-world
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 29, 2024 8:01am
New Press Release - Biovaxys Signs Binding Letter of Intent to Develop DPX(TM)-Based Vaccines for Life Threatening Food Allergies
VANCOUVER, BC, July 29, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX™ platform, is pleased to announce that...
read article.
(0)
•••
JoseCuervo
X
View Profile
View Bullboard History
Comment by
JoseCuervo
on Jul 25, 2024 12:50pm
RE:WHY such low offer ??
You have to offer at a discount to attract investors to participate. Currently market value is $0.065 so $0.05 is not too bad.
(76)
•••
Humanist
X
View Profile
View Bullboard History
Post by
Humanist
on Jul 23, 2024 11:34pm
WHY such low offer ??
but one thing makes me feel a bit comfortable is that the CEO & VARIOUS DIRECTORS are participating in the offerings. however i was hoping for a better annoncement after the few mths wait. let
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.
Why Dozens of Pro Athletes are Paying Attention to this Product
Q Precious & Battery Metals To Resume Diamond Drilling La Corne South Project, Val D'or Quebec
Webinar Dec. 12, 2024: Transforming Regenerative Medicine. Register Now